Published in AIDS Weekly, July 3rd, 2006
"PEG-IFN has become standard therapy for HCV infection. We evaluated whether PEG-IFN pharmacodynamics and pharmacokinetics account for differences in treatment outcome and whether these parameters might be predictors of therapeutic outcome," wrote A.H. Talal and colleagues, Cornell University.
"Twenty-four IFN-naive, HCV/human immunodeficiency virus-coinfected patients received PEG-IFN alpha-2b (1-5 mcg/kg) once weekly plus daily...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.